Literature DB >> 19961904

Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain.

J Mika1, E Rojewska, W Makuch, B Przewlocka.   

Abstract

A role of neuropeptides in neuropathic pain development has been implicated; however, the neuroimmune interactions that are involved in the underlying mechanisms may be more important than previously thought. To examine a potential role of relations between glia cells and neuropeptides in neuropathic pain, we performed competitive reverse-transcription polymerase chain reaction (RT-PCR) from the dorsal lumbar spinal cord and the dorsal root ganglion (DRG) after chronic constriction injury (CCI) in the rat sciatic nerve. The RT-PCR results indicated that complement component 1, q subcomponent (C1q) mRNA expression was higher than glial fibrillary acidic protein (GFAP) in the spinal cord 3 and 7 days post-CCI, suggesting that spinal microglia and perivascular macrophages are more activated than astrocytes. In parallel, we observed a strong upregulation of prodynorphin mRNA in the spinal cord after CCI, with no changes in the expression of proenkephalin or pronociceptin. Conversely, the expression of GFAP mRNA in the DRG was higher than C1q, which suggests that the satellite cells are activated shortly after injury, followed by the macrophages and polymorphonuclear leukocytes infiltrating the DRG. In the DRG, we also observed a very strong upregulation of prodynorphin (1387%) as well as pronociceptin (122%) and a downregulation of proenkephalin (47%) mRNAs. Interestingly, preemptive and repeated i.p. injection of minocycline reversed the activation of microglia/macrophages in the spinal cord and the trafficking of peripheral immune cells into the DRG, and markedly diminished the upregulation of prodynorphin and pronociceptin in the DRG. We thus provide novel findings that inhibition of C1q-positive cells by minocycline can diminish injury-induced neuropeptide changes in the DRG. This suggests that immune cells-derived pronociceptive factors may influence opioid peptide expression. Therefore, the injury-induced activation of microglia and leukocytes and the subsequent activation of neuropeptides involved in nociception processes are potential targets for the attenuation of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961904     DOI: 10.1016/j.neuroscience.2009.11.064

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  38 in total

Review 1.  Tetracyclines and pain.

Authors:  Leandro F S Bastos; Antônio C P de Oliveira; Linda R Watkins; Márcio F D Moraes; Márcio M Coelho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-27       Impact factor: 3.000

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

Review 3.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

4.  Satellite glial cell proliferation in the trigeminal ganglia after chronic constriction injury of the infraorbital nerve.

Authors:  Macayla Donegan; Melanie Kernisant; Criselda Cua; Luc Jasmin; Peter T Ohara
Journal:  Glia       Date:  2013-10-03       Impact factor: 7.452

5.  Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats.

Authors:  H Nie; H Zhang; H R Weng
Journal:  Neuroscience       Date:  2010-08-03       Impact factor: 3.590

6.  Effects of surgery and/or remifentanil administration on the expression of pERK1/2, c-Fos and dynorphin in the dorsal root ganglia in mice.

Authors:  A Romero; A González-Cuello; M L Laorden; A Campillo; N Vasconcelos; E Romero-Alejo; M M Puig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-30       Impact factor: 3.000

7.  North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.

Authors:  Alexis D Leal; Rui Qin; Pamela J Atherton; Paul Haluska; Robert J Behrens; Charles H Tiber; Patanit Watanaboonyakhet; Matthias Weiss; Paul T Adams; Travis J Dockter; Charles L Loprinzi
Journal:  Cancer       Date:  2014-03-11       Impact factor: 6.860

8.  Can satellite glial cells be therapeutic targets for pain control?

Authors:  Luc Jasmin; Jean-Philippe Vit; Aditi Bhargava; Peter T Ohara
Journal:  Neuron Glia Biol       Date:  2010-06-22

9.  Topography of microglial activation in sensory- and affect-related brain regions in chronic pain.

Authors:  Anna M W Taylor; Sadaf Mehrabani; Steve Liu; Alison J Taylor; Catherine M Cahill
Journal:  J Neurosci Res       Date:  2016-08-30       Impact factor: 4.164

Review 10.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.